The DUO readout triggered a $6 million milestone payment to Infinity Pharmaceuticals Inc. (NASDAQ:INFI), which granted Verastem exclusive, worldwide rights to duvelisib last November. Infinity is eligible for an additional $22 million upon the candidate's first regulatory approval, plus tiered mid- to high-single-digit royalties. Infinity has rights to duvelisib from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) (see BioCentury Extra, Nov. 2, 2016).
Last June, AbbVie Inc. (NYSE:ABBV) returned to Infinity rights to co-develop duvelisib after the candidate led to a smaller than expected clinical benefit in DYNAMO (see BioCentury Extra, June 28, 2016).
By year end, Verastem also plans to start a Phase II trial of duvelisib to treat peripheral T cell lymphoma (PTCL), for which the product has Fast Track designation in the U.S. Duvelisib is an oral inhibitor of phosphoinositide-3-kinase (PI3K) delta and gamma.
投資の参考になりましたか？
